Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows Aug. 18)
Stocks In Focus
Coherus Announces Positive Late-Stage Data From Lung Cancer Study
Coherus Biosciences, Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences announced positive interim results from the pivotal Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer.
The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival compared to chemotherapy alone.
Coherus shares were jumping 21.07% to $17.12 in premarket trading.
Paratek's Antibiotic Gets Orphan Drug Designation For Bacterial Infection
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) said the Food and Administration has granted orphan drug designation for Nuzyra in the treatment of infections caused by nontuberculous mycobacteria.
This orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex, which is the focus of an ongoing Phase 2b study initiated by Paratek.
The stock was slipping 1.73% to $5.12 in premarket trading.
Related Link: The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Illumina Acquires Cancer Diagnostics Company Grail
Illumina first announced its intention to acquire GRAIL nearly a year ago, four years after it was spun off. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic.
The stock was down 0.46% at $508.26.
Click here to access Benzinga's FDA Calendar.
Adagene Announces Clinical Study Collaboration For Evaluating ADG106-Keytruda Combo In Solid Tumor/Hematological Malignancies
See also: BEST CANCER INSURANCE
On The Radar
Clinical Readouts
Fate Therapeutics, Inc. (NASDAQ:FATE) is scheduled to present at an investor event new Phase 1 data from FT516 and FT596 programs in relapsed/refractory lymphoma.
Plus Therapeutics, Inc. (NASDAQ:PSTV) will present at the Conference on Brain Metastases, hosted by the Society for Neuro-Oncology, data from one planned clinical trial and one completed preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome for the treatment of leptomeningeal metastases.
Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
